NCT05172700 2024-12-18
Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer
Eli Lilly and Company
Approved for marketing
Clinical Trials
3 trialsNCT02437019 2017-03-20
Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Janssen-Cilag Farmaceutica Ltda.
Approved for marketing
NCT02136511 2014-10-28
Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia
Gilead Sciences
Approved for marketing